LOGIN / REGISTER SUBSCRIBE
Tuesday, September 9, 2025

@2024 - All Right Reserved.  Opiniguru

Home BusinessLilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says
Business

Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says

by opiniguru
written by opiniguru 0 comments

[ad_1]

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images

[ad_2]

Source link

opiniguru

You may also like

CNA Explains: How hard could Trump’s 50% tariff hit India?

Dylan Field, Figma’s 33-year-old cofounder, is a former LinkedIn intern who launched the...

Taiwan adds China's Huawei, SMIC to export control list

Trump administration gutted program aimed at preventing targeted violence

Northern Trust's SWOT analysis: wealth franchise strength amid credit concerns

Five9's SWOT analysis: ai-driven growth boosts cloud contact center stock

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.